Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Evolus, Inc. despite higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Evolus is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of -28.6%, while revenues are projected to be $82.93 million, an increase of 23.9% from the previous year [3]. - The earnings report is scheduled for August 5, and better-than-expected results could lead to a stock price increase, whereas missing estimates may result in a decline [2]. Estimate Revisions - The consensus EPS estimate for Evolus has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for Evolus is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -28.57%, suggesting a bearish sentiment among analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is stronger for positive readings [8][9]. - Evolus currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat based on the combination of a negative Earnings ESP and the rank [11]. Historical Performance - In the last reported quarter, Evolus was expected to post a loss of $0.10 per share but actually reported a loss of -$0.18, resulting in a surprise of -80.00% [12]. - The company has not beaten consensus EPS estimates in any of the last four quarters, indicating a trend of underperformance [13]. Industry Comparison - ResMed, a peer in the Zacks Medical - Products industry, is expected to report earnings per share of $2.46 for the same quarter, reflecting a year-over-year change of +18.3%, with revenues projected at $1.32 billion, up 8.2% from the previous year [17]. - ResMed's consensus EPS estimate has been revised up by 0.5% over the last 30 days, and it has a positive Earnings ESP of +5.16%, suggesting a likelihood of beating consensus estimates [18].